Revolution Medicines (RVMD) Free Cash Flow (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Free Cash Flow of -$355.0 million for Q1 2026, down 79.98% year-over-year from -$1.8 billion in Q1 2025, and down 27.91% quarter-over-quarter from -$277.5 million in Q4 2025.
Revolution Medicines (RVMD) Free Cash Flow (2019 - 2026) Analysis & Trends
Revolution Medicines' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$355.0 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 79.98% year-over-year to -$355.0 million; the TTM figure through Mar 2026 stood at -$1.1 billion (down 79.84% YoY), while the FY2025 annual figure was -$913.7 million, down 63.45% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$355.0 million, down from -$277.5 million in the prior quarter.
- The five-year high for Free Cash Flow was -$51.6 million in Q3 2022, with the low at -$355.0 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$130.8 million (2024), against an average of -$141.6 million.
- Peak annual rise in Free Cash Flow reached 11.05% in 2024, while the deepest fall reached 154.11% in 2024.
- Revolution Medicines' Free Cash Flow stood at -$61.3 million in 2022, then sank by 92.17% to -$117.8 million in 2023, then retreated by 11.05% to -$130.8 million in 2024, then sank by 112.2% to -$277.5 million in 2025, then declined by 27.91% to -$355.0 million in 2026.
- Business Quant data shows RVMD's Free Cash Flow at -$355.0 million in Q1 2026, -$277.5 million in Q4 2025, and -$209.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -268.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -389.61 Mn |
| Jun 30, 2026 | -389.61 Mn |
| Mar 31, 2026 | -354.95 Mn |
| Mar 31, 2026 | -354.95 Mn |
| Dec 31, 2025 | -277.51 Mn |
| Dec 31, 2025 | -277.51 Mn |
| Sep 30, 2025 | -209.31 Mn |
| Sep 30, 2025 | -209.31 Mn |
| Jun 30, 2025 | -229.69 Mn |
| Jun 30, 2025 | -229.69 Mn |
| Mar 31, 2025 | -197.22 Mn |
| Mar 31, 2025 | -197.22 Mn |
| Dec 31, 2024 | -130.78 Mn |
| Dec 31, 2024 | -130.78 Mn |
| Sep 30, 2024 | -133.94 Mn |
| Sep 30, 2024 | -133.94 Mn |
| Jun 30, 2024 | -133.86 Mn |
| Jun 30, 2024 | -133.86 Mn |
| Mar 31, 2024 | -160.44 Mn |
| Mar 31, 2024 | -160.44 Mn |